## Consolidated Financial Results for the Three Months Ended September 30, 2016 [Japanese GAAP]



October 28, 2016

Company name: KAWANISHI HOLDINGS, INC. Stock exchange listing: Tokyo Stock Exchange Code number: 2689 URL: http://www.kawanishi-md.co.jp/ Representative: Yohei Maeshima, President COO Contact: Nobuharu Murata, Director and General Manager, Administrative Department Phone: +81-86-236-1115 Scheduled date of filing quarterly securities report: November 14, 2016 Scheduled date of commencing dividend payments: -Availability of supplementary briefing material on quarterly financial results: Unavailable Scheduled of quarterly financial results briefing session: Not scheduled

### (Amounts of less than one million yen are rounded down.) 1. Consolidated Financial Results for the Three Months Ended September 30, 2016 (July 1, 2016 to September 30, 2016)

(1) Consolidated Operating Results

(% indicates changes from the previous year.)

(1) consonance ope	rading reesand	(70 maleates enanges from the previous year.)						
	Net sales	5	Operating inc	come	Ordinary inco	ome	Net income attributable to owners of parent	
Three months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
September 30, 2016	25,459	10.2	41	—	52	—	20	—
September 30, 2015	23,103	2.8	(72)	_	(70)	—	(72)	—

(Note) Comprehensive income: Three months ended September 30, 2016: ¥11 million [-%]

Three months ended September 30, 2015: ¥(89) million [-%]

	Basic earnings per share	Diluted earnings per share		
Three months ended	Yen	Yen		
September 30, 2016	3.72	—		
September 30, 2015	(12.94)	—		

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
	Million yen	Million yen	%
As of September 30, 2016	32,641	4,552	13.6
As of June 30, 2016	31,049	4,593	14.8

(Reference) Equity: As of September 30, 2016: ¥4,435 million As of June 30, 2016: ¥4,593 million

#### 2. Dividends

	Annual dividends							
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total			
	Yen	Yen	Yen	Yen	Yen			
Fiscal year ended June 30, 2016	-	0.00	—	30.00	30.00			
Fiscal year ending June 30, 2017	_							
Fiscal year ending June 30, 2017 (Forecast)		0.00	_	30.00	30.00			

(Note) Revision to the forecast for dividends announced most recently: No

# 3. Consolidated Financial Results Forecast for the Fiscal Year Ending June 30, 2017 (July 1, 2016 to June 30, 2017)

(%	indicates	changes	from	the	previous	corresponding	period.)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First half	52,885	7.4	463	138.1	462	139.1	259	184.0	46.29
Full year	105,069	3.6	816	50.2	808	45.2	492	61.1	87.77

(Note) Revision to the financial results forecast announced most recently: No

#### Notes:

 Changes in significant subsidiaries during the period under review (changes in specified subsidiaries resulting in changes in scope of consolidation): Yes

Newly consolidated: 1 company (Company Name); EXSOLA MEDICAL Inc.

- (2) Accounting policies adopted specially for the preparation of quarterly consolidated financial statements:
- (3) Changes in accounting policies, changes in accounting estimates and retrospective restatement
  - 1) Changes in accounting policies due to the revision of accounting standards: No
  - 2) Changes in accounting policies other than 1) above: No
  - 3) Changes in accounting estimates: No
  - 4) Retrospective restatement: No
- (4) Total number of issued shares (common stock)
  - Total number of issued shares at the end of the period (including treasury stock): September 30, 2016: 6,250,000 shares June 30, 2016: 6,250,000 shares
  - 2) Total number of treasury stock at the end of the period: September 30, 2016: 639,284 shares June 30, 2016: 639,284 shares
  - 3) Average number of shares during the period: Three months ended September 30, 2016: 5,610,716 shares Three months ended September 30, 2015: 5,610,762 shares
- \* Presentation regarding the implementation status of the quarterly review procedures

These quarterly financial results are outside the scope of quarterly review procedures under the Financial Instruments and Exchange Act, and at the time of disclosure of these quarterly financial results, review procedures for the quarterly financial statements under the Financial Instruments and Exchange Act have not been completed.

\* Explanation of the proper use of financial results forecast and other notes

The figures forecast above are based on information that is available as of the date of publication of this document, and contain a wide range of uncertain factors. Actual results may differ significantly from these figures due to factors such as changes in the business environment.